Skip to main content
. 2019 Feb 23;12(2):100011. doi: 10.1016/j.waojou.2019.100011

Fig. 4.

Figure 4

Treatment and type of response according to UAS and/or UCT. (A) Treatment response over time shown as a percentage of patients that achieved response at each month. Treatment response was defined as an UAS7 ≤6 and/or UCT ≥12. (B) Type of responders according to how long they took to achieve response with each omalizumab dose. Mo, month; Early responders, response at first month; Intermediate responders, response between the first and third month; Late responders, response after the sixth month; UAS7, Urticaria Activity Score 7; UCT, Urticaria Control Test. CU-Q2oL, Chronic Urticaria Quality of Life.